Kezar Life Sciences Inc. (NASDAQ:KZR) shares traded 0.92% higher at $7.68 on Wall Street last session.
In accordance with the data, 6 analysts cover Kezar Life Sciences Inc. (NASDAQ:KZR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $17.00, we find $17.00. Given the previous closing price of $7.61, this indicates a potential upside of 123.39 percent. KZR stock price is now -2.74% away from the 50-day moving average and -23.41% away from the 200-day moving average. The market capitalization of the company currently stands at $518.86M.
It has been rated a hold by 0 analysts and a buy by 6. Brokers who have rated the stock have averaged $18.00 as their price target over the next twelve months.
With the price target of $19, Wells Fargo recently initiated with Overweight rating for Kezar Life Sciences Inc. (NASDAQ: KZR)., while ‘Wells Fargo’ rates the stock as ‘Outperform’.
In other news, Morningside Venture Investment, 10% Owner sold 3,612 shares of the company’s stock on Oct 04. The stock was sold for $31,857 at an average price of $8.82. Upon completion of the transaction, the 10% Owner now directly owns 6,076,740 shares in the company, valued at $46.67 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 03, 10% Owner Morningside Venture Investment sold 28,700 shares of the business’s stock. A total of $251,957 was realized by selling the stock at an average price of $8.78. This leaves the insider owning 6,080,352 shares of the company worth $46.7 million. Insiders disposed of 37,312 shares of company stock worth roughly $0.29 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KZR stock. A new stake in Kezar Life Sciences Inc. shares was purchased by NOVO HOLDINGS A/S during the first quarter worth $4,596,000. WOODLINE PARTNERS LP invested $4,456,000 in shares of KZR during the first quarter. In the first quarter, NORGES BANK acquired a new stake in Kezar Life Sciences Inc. valued at approximately $3,775,000. RAFFERTY ASSET MANAGEMENT, LLC acquired a new stake in KZR for approximately $1,878,000. SLOW CAPITAL, INC. purchased a new stake in KZR valued at around $1,157,000 in the second quarter. In total, there are 196 active investors with 85.80% ownership of the company’s stock.
Kezar Life Sciences Inc. (NASDAQ: KZR) opened at $7.63 on Wednesday. During the past 12 months, Kezar Life Sciences Inc. has had a low of $4.30 and a high of $18.55. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 31.20, and a quick ratio of 31.20. The fifty day moving average price for KZR is $7.90 and a two-hundred day moving average price translates $10.03 for the stock.
The latest earnings results from Kezar Life Sciences Inc. (NASDAQ: KZR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.25, beating analysts’ expectations of -$0.27 by 0.02. This compares to -$0.28 EPS in the same period last year. The company reported revenue of $18.93 million for the quarter, compared to $14.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 30.54 percent.
Kezar Life Sciences Inc.(KZR) Company Profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.